Kairos Pharma financials
$1.66−1.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating income | -$1.4M | -$1.7M | -$1.4M | -$1.4M | -$1.5M | -$1.3M | -$1.4M | -$383.0K |
| Net income | -$1.4M | -$1.7M | -$1.4M | -$1.4M | -$1.4M | -$1.3M | -$980.0K | -$1.0M |
| Net margin | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.42 | $-0.56 | $-0.47 | $-0.49 | $-0.56 | $-0.56 | $-0.51 | $-0.70 |
| EBITDA | -$1.6M | -$1.4M | $795.0K | -$2.7M | -$1.4M | -$1.2M | -$1.4M | -$343.0K |
| Operating cash flow | -$1.0M | -$1.0M | -$1.1M | -$838.0K | -$805.0K | -$714.0K | -$1.8M | -$2.0M |
| Free cash flow | -$1.0M | -$1.0M | -$1.1M | -$838.0K | -$805.0K | -$714.0K | -$1.8M | -$2.0M |
| Diluted shares | 3.1M | 3.0M | 2.9M | 2.9M | 2.5M | 2.3M | 1.9M | 1.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.6M | $3.7M | $4.5M | $5.6M | $3.0M | $3.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $4.5M | $5.7M | $6.5M | $8.1M | $6.7M | $7.9M |
| Total liabilities | $265.0K | $431.0K | $199.0K | $402.0K | $676.0K | $805.0K |
| Shareholders' equity | $4.2M | $5.3M | $6.3M | $7.7M | $6.0M | $7.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology